Gynaecology - Investigations Flashcards

1
Q

POP (pelvic organ prolapse) investigations

A

• Examination
o Abdominal examination
o Examine patient with them in both standing + left lateral position
o Ask the woman to strain + observe both whilst standing + supine
o Sim’s speculum – inserted along the posterior vaginal wall to assess the anterior wall + vaginal vault + vice versa – ask pt to strain
o Bivalve speculum – to identify the cervix or the vaginal vault
 Ask pt to strain
 Slowly remove speculum
 Look for the degree of descent of the vaginal apex
o If prolapse protrudes beyond the hymen
 Ulceration and hypertrophy of the cervix or vaginal mucosa with concomitant bleeding
o Rectal examination if there are bowel symptoms

For urinary symptoms 
•	Urine dip
•	Speculum examination
•	Bladder diary (3 days)
•	Residual volume
•	Urodynamics
•	Cystoscopy
•	Renal USS

• Dx is usually clinical + based on hx + examination
o Speculum – grade and severity

•	For urinary symptoms
o	Urine dip – Urinalysis +/- MSU
o	Post-void residual volume testing using a catheter or bladder USS
o	Urodynamic investigations
o	Urea and Creatinine
o	Renal USS

• For bowel symptoms
o Anal manometry
o Defecography
o Endo-anal USS – to look for an anal sphincter defect if faecal incontinence is present)

• USS or MRI

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

USI urinary stress incontinence investigations

A

• A full obstetric history should be taken in women

• Examination (speculum)
o Digital assessment of pelvic floor muscle contraction (Kegel exercises)
o Bimanual/vaginal examination to assess for the presence of prolapse
o Ask patient to cough (Valsalva) during exam to check for fluid leakage
o Look for signs of vaginal atrophy
o Perform an abdominal/pelvic/neurological examination

• Bladder diaries – 1st line
o Minimum of 3 days

• Urine dipstick testing (+/-MSU) – 1st line
o Look for blood, glucose, protein, leukocytes, nitrites
o Rule out UTI or DM

• Urodynamic studies – 2nd line
o Multi-channel cystometry, ambulatory urodynamics, video urodynamics
o After you start conservative treatment but before surgery for urinary incontinence
o Multi-channel filling + voiding cystometry should not be performed in women in whom pure stress or stress-predominant mixed urinary incontinence is identified by hx or examination
o Multichannel filling and voiding cystometry before surgery for stress urinary incontinence if
 Urge-predominant mixed urinary incontinence or urinary incontinence in which type is unclear
 Symptoms suggestive of voiding dysfunction
 Anterior or apical prolapse / cystocele
 Hx of previous surgery for stress urinary incontinence
o Consider ambulatory urodynamis/videourodynamics if dx remains unclear after conventional urodynamics

Other ix:
• Renal function tests

• Assessment of residual urine
o Post-void residual volume using a bladder scan
o Measure in women who have symptoms suggesting voiding dysfunction or recurrent UTI
o Can also be assessed using catheterisation

• Symptom scoring + QOL
o Use a validated urinary incontinence-specific symptom + WOL questionnaire when therapies are being evaluated

• Cystoscopy

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

OAB overactive bladder syndrome investigations

A

• Dx made from the symptoms

• Speculum examination
o Exclude pelvic organ prolapse
o Assess ability to initiate voluntary contraction of pelvic floor muscles (Kegel exercises)
o Ask patient to cough (Valsalva) during exam to check for fluid leakage

• Urine dipstick + MSU – 1st line
o Rule out UTI or DM

• Bladder diaries – 1st line
o Minimum of 3 days

• Urodynamic studies – 2nd line
o To confirm the diagnosis
o Show involuntary contraction of the bladder during filling
o Multichannel cystometry
 3 pressures measured from inside rectum + urethra
 Bladder pressure = detrusor + IAP (intraabdominal pressure)
 Detrusor = bladder – IAP
o Urinary flow rate
 Men can hold 400ml and void at a rate of 10-15ml/s
 Women can hold 500ml and void at a rate of 15-20ml/s

• Depending on presentation
o USS of the renal tract + cystoscopy
o Ix to consider differential dx – blood tests for renal function, electrolytes, calcium, fasting glucose

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

PID (pelvic inflammatory disease) investigations

A
  • Start Abx before swabs if you suspect PID
  • Pregnancy test – rule out ectopic pregnancy

• Triple swabs (2 x EC, 1x HVS)
o Cervical swabs for chlamydia + gonorrhoea
o A positive result supports dx of PID, a negative result does not exclude PID

• Speculum – look for signs of inflammation/discharge

• Bimanual – cervical excitation, adnexal masses (tubo-ovarian abscess)
o If tubo-ovarian abscess, confirm with TVUSS

  • raised ESR, CRP
  • If febrile – blood cultures, FBC, CRP
  • Endometrial biopsy + USS

• Laparoscopy
o Direct visualisation of the fallopian tubes – the best single diagnostic test
o Invasive procedure + not appropriate in routine clinical practice

  • Urinalysis to exclude UTI
  • USS to exclude other conditions
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

Bartholin’s cysts ix

A

• Swab from the contents of the cyst (often organisms are skin commensals)

• If >40
o Biopsy to rule out carcinoma of the vulva
o A number of types of malignancy can present in this way
o Carcinoma of the Bartholin’s gland – 5% of vulval carcinoma

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

Endometriosis ix

A
•	Acute setting 
bloods
urinalysis + MC+S
cervical swabs
βHCG – helpful in excluding important differentials 

• TVUSS can be used to:
o Investigate suspected endometriosis
o Make and to exclude the diagnosis of an ovarian endometrioma
o Identify deep endometriosis involving the bowel, bladder or ureter
o Association to clear cell + endometroid ovarian carcinoma
o If TVUSS not acceptable. consider a transabdominal USS

• Laparoscopy – the only reliable diagnostic test, gold standard
o Can be used to diagnose endometriosis if clinical suspicion remains or symptoms persist, even if USS was normal
o Active lesions = red vesicles or puncuae marks on peritoneum
o Less active endometriosis = white scars/brown spots
o Consider taking a biopsy to: a) confirm the dx, b) exclude malignancy (if an endometrioma is treated but not excised)
o Small risk of major complications – bowel perforation
o For women with suspected deep endometriosis involving bowel/bladder/ureter – consider a pelvic US or MRI before an operative laparoscopy

• Abdominal and pelvic examination for women with ?endometriosis – bimanual + speculum examination
o Identify abdominal masses + pelvic signs –
 decreased organ mobility + enlargement
 Tender nodularity in the posterior vaginal fornix
 Visible vaginal endometriotic lesions
 Fixed retroverted uterus (ectopic tissue on utero-sacral ligament)
o If pelvic examination not appropriate, offer abdominal examination to exclude abdominal masses

• Pelvic MRI
o Should not be used as the primary ix for dx
o Should be used to assess the extent of deep endometriosis involving the bowel, bladder, ureter before diagnostic/surgical laparoscopy
o Pelvic MRI before operative laparoscopy

• AFS (american fertility society) /ASRM (american society for reproductive medicine) – classification system that classifies endometriosis as minimal (stage I), mild (stage II), moderate (Stage III)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

Fibroids investigations

A
  • Abdominal examination
  • Pregnancy test
  • FBC (anaemia), iron studies

• Pelvic USS
o To exclude other causes of a pelvic mass
o To confirm presence + size of fibroids
o To exclude complications (e.g. urinary tract obstruction causing hydronephrosis)
o TVUSS is more accurate

  • MRI – if USS is not definitive + myomectomy is being considered
  • Submucous fibroids – saline infusion US
  • Leiomyosarcoma – LDH, LDH isoenzyme 3, gadolinium enhanced MRI
  • Abnormal uterine bleeding – Endometrial sampling (Pipelle)
  • Hysteroscopy with biopsies
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

Cervical ectropion investigations

A
Speculum – red outer cervix due to shift of transformation zone
Then colposcopy (1st line) to visualise suspicious area
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

Endometrial polyp investigations

A

o Pelvic US/TVUSS – 1st line ix – endometrial thickening

o OPH (outpatient hysteroscopy)

o SIS (saline infusion sonography)

 OPH + SIS are the most accurate

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

Menopause ix

A

• Clinical dx, investigations not usually recommended
• Pregnancy test
• Laboratory tests not required in the following otherwise healthy women >45 with menopausal symptoms
o Perimenopause = vasomotor symptoms + irregular periods
o Menopause = women who have not had a period for at least 12 months and are not using hormonal contraception
o Menopause in women without uterus = based on symptoms

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

Investigations undertaken in some women with menopausal symptoms

A

• FSH levels
o Two levels are required 2 or 6 weeks apart
o Considered FSH testing to dx menopause only
 In women aged 40-45 years with menopausal symptoms incl. a change in their menstrual cycle (? early menopause)
 In women aged <40 years in whom POI is suspected (?POI)
 Women >50 years who are amenorrhoeic and taking the POP/have an implant or a Mirena fitted who wish to consider stopping contraception
• >30 nmol/L, continue contraception for 1 year and then stop (there is no need to repeat this test)
• <30 nmol/L, continue with contraception and recheck FSH after 1 year.

o No need for the FSH level to be tested in most women
o Do not use FSH to dx menopause in women using COCP and progestogen contraception or high-dose progestogen
o A raised FSH it not diagnostic for the menopause – a high level will just indicate a lack of ovarian response at a point in time

• To rule out alternative dx – TFT, Blood glucose, prolactin, TVUSS (endometrial/ovarian cancer- bleeding = endometrial, no bleeding and mass = ovarian)

  • Blood cholesterol and triglycerides – consider if the woman has any CV RF
  • Cervical screening and mammograms – ensure the woman is up to date
  • A pelvic scan – for women with atypical symptoms
  • Tests that should not be used to dx perimenopause or menopause in women >45 years = anti-mullerian hormone, inhibin A or B, estradiol, antral follicle count, ovarian volume
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

Atrophic vaginitis ix

A

• May not be necessary if the dx is clear

• May be needed to exclude other problems
o Postmenopausal bleeding that requires investigation
o Infection – if there is discharge or bleeding
o Other causes of recurrent UTI
o Screen for diabetes may be considered

• Other ix
o Vaginal pH testing
 Sample from mid-vagina, not the posterior fornix
 Result: more alkaline in atrophic vaginitis

o Vaginal cytology
 Lack of maturation of the vaginal epithelium (typical of atrophic vaginitis)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

Asherman’s syndrome ix

A

• Hysteroscopy
o Gold standard
o Direct visualisation of the uterus
o Most reliable method for diagnosis

• Saline hysterosonography

• TVUS
o Subendothelial linear striations
o Boggy uterus

• Hysterosalpingogram
o Injection of a contrasting fluid into the uterus in order for an X-ray imaging to be generated
o Allows for the imaging of the uterine cavity shape which may be abnormal in the presence of intrauterine adhesions

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

Describe these findings in the 5 types of miscarriage + septic miscarriage

Threatened
Inevitable
Missed (delayed/late) miscarriage 
Incomplete miscarriage
Complete miscarriage
\+ Septic miscarriage
Bleeding
Pain
Os
TVUSS state of pregnancy
Fetal heartbeat=viability
A
Threatened
Bleeding Yes
Pain No 
Os Closed
TVUSS state of pregnancy Present 
Fetal heartbeat=viability Present
25-50% progress to c complete miscarriage 
associated with a risk of subsequent preterm delivery
Inevitable
Bleeding Yes (heavy, clots)
Pain Yes
Os Open
TVUSS state of pregnancy Present, may be lower in the uterus
Fetal heartbeat=viability No
Progresses to (in)complete
Missed (delayed/late) 
Bleeding Normally asymptomatic
Pain Normally asymptomatic 
Os Closed
TVUSS state of pregnancy Present 
Fetal heartbeat=viability No
other:
CRL >7mm
GS >25mm
uterus is small for dates
pregnancy test can remain positive for several days/weeks but early pregnancy symptoms may have decreased or stopped
hx of threatened miscarriage + persistent dark-brown discharge
Incomplete miscarriage
Bleeding Yes
Pain Yes
Os Open
TVUSS state of pregnancy RPOC
Fetal heartbeat=viability No
Complete miscarriage
Bleeding resolved
Pain resolved
Os closed
TVUSS state of pregnancy empty
Fetal heartbeat=viability No
Septic miscarriage
Bleeding light bleeding
Pain yes
Os slightly open
TVUSS state of pregnancy RPCO
Fetal heartbeat=viability No
occurs with incomplete miscarriage
signs of infection (temperature, foul smelling discharge, tachy, abdo pain)
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

Miscarriage ix

A

• Pregnancy test –> speculum (inspect Os) –> TVUS (FH (Foetal heartrate) –> CRL (Crown-rump length) /foetal pole or GS (Gestational sac) / YS (Yolk sac)
o Speculum – quantity + location of bleeding, os open/closed, can remove any products
o Abdo exam – exclude ectopic (=unilateral tenderness, cervical excitation, adnexal mass) (do not perform a PV exam if suspecting an ectopic - might rupture)

• TVUS
o Dating pregnancies using USS

 <14 weeks –> CRL
A foetal pole may not be seen until 9 weeks

 >14 weeks –> AC, HC, FL

o Need GS + YS to be a viable IUP – otherwise PUL

o Process of TVUS
 If there is no visible heartbeat – second scan should be performed at minimum of 7 or 14 days
 Look for FH –> foetal poles (either crown or rump) or CRL –> if not foetal pole, look for GS
Miscarriage [cannot be diagnosed as miscarriage on 1 USS alone – get 2nd opinion/re-scan] if
• No FH + CRL >7mm
• GS >25mm + no foetus

PUV (pregnancy of unknown viability) –> TVUS in 7 days if
• No FH + CRL <7mm
• GS <25mm + no foetus

• Serum hcg
o Can help exclude an ectopic pregnancy in women with a complete miscarriage or PUL
o Serial tests are required – they should complement clinical assessment and not replace it
o Two tests are taken 48 h apart
 >63% increase – ongoing pregnancy
 >50% decrease – pregnancy is unlikely to continue
 Consider rare causes of raised hcg – gestational trophoblastic disease, cranial gem cell tumour

•	RMC (recurrent miscarriage)
o	Cytogenic analysis of products of conception
o	Pelvic USS (structural abnormalities)
o	Anti-phospholipid antibodies
o	Anticardiolipin antibodies
o	Screen for BV (bacterial vaginosis)
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

gestational trophoblastic disease ix

A

• URINE AND BLOOD LEVELS OF β-hcg
o Molar pregnancy
 Blood βhcg grossly elevated – will be very high for gestation
 Βhcg similar to TSH - low TSH, high T4

o Malignancy
 Persistently raised βhcg or rising after ERCP (evacuation of retained products of conception)
 FBC, LFTs (mets)

o Urine pregnancy test should be performed in all cases of persistent or irregular vaginal bleeding >8 weeks after a pregnancy event
o Women with persistent abnormal vaginal bleeding after a non-molar pregnancy should undergo a pregnancy test to exclude persistent GTN
o Women who receive care for a miscarriage should be recommended to do a urine pregnancy test 3 weeks after miscarriage
o Women who undergo medical abortions should be recommended to do a urine pregnancy test 3 weeks after the procedure
o Used as a biomarker
o Bhcg May be of value in diagnosing molar pregnancies but are far more important in disease follow-up

• HISTOLOGY
o To make a definitive diagnosis
o The diagnosis of complete mole, partial mole, atypical PSN, PSTT, ETT require histological confirmation
o The diagnosis of GTN does not require histological confirmation
o All products of conception from a non-viable pregnancy/miscarriages obtained from medical or surgical treatment should undergo histological examination to exclude trophoblastic disease/neoplasia if no fetal parts are identified at any stage of the pregnancy
o No need to routinely send products of conception for histological assessment after TOP, provided foetal parts have been identified on prior US
o All forms of GTD have distinctive morphological features, depending on which tissues they are derived from

• PELVIC USS
o USS in the first trimester may not be reliable
o Second trimester

o	Complete mole:
	Snowstorm appearance
	Cluster of grapes
	No foetal parts
	Heterogeneous mass with not fetal development
	Theca-lutein ovarian cysts 

o Incomplete mole
 No snowstorm/cluster of grapes
 Foetal parts

o Malignancy
 Snowstorm, vesicles or cysts

• STAGING ix where metastatic disease is suspected
o Doppler pelvic USS for local pelvic spread + vascularity
o CXR or lung CT – lung metastases
o Liver/Intra-abdominal masses CT – CT CAP
o MRI scan – brain mets

Staging - FIGO staging system
Disease risk - FIGO staging for GTD
https://www.obgproject.com/wp-content/uploads/2018/06/thumbnail.jpg

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
17
Q

gestational trophoblastic disease staging

A

FIGO

o Stage I – disease confined to the uterus
o Stage II – extends outside the uterus but is limited to the genital structures (adnexa, vagina, broad ligament)
o Stage III – extends to the lungs +/- genital tract involvement
o Stage IV – all other metastatic sites

18
Q

PCOS ix

A

• Raised LH
• FSH normal
• Raised LH:FSH ratio (>2)
o These 3 parameters are not part of the diagnostic criteria and may be normal
o Oral contraceptive pills affect levels
o Helps to exclude premature ovarian insufficiency (LH + FSH both raised) + hypogonadotropic hypogonadism (LH + FSH reduced)

• Total testosterone – normal to slightly raised
o If total testosterone is >5 nmol/L, exclude androgen-secreting tumours and CAH
• Free testosterone – may be raised
• SHBG – normal to low
o Can be used to calculate the free androgen index = (100 x total testosterone)/SHBG
• Free androgen index – normal or elevated
o Can be used as an alternative to measuring free testosterone if this is not locally available

• Transvaginal/pelvic USS
o Pearl necklace sign
o Characteristic ovaries (the average volume is 3x that of normal ovaries)
o Increased ovarian volume >10mL in either or both ovaries
o 12 or more follicles in each ovary (measuring 2-9 mm)
and/or

• Tests to exclude other causes –
TFT
17-hydroxyprogesterone levels (CAH, excludes 21-hydroxylase deficiency)
prolactin (hyperprolactinaemia)
DHEA-S + free androgen index (androgen-secreting tumours)
24-h urinary cortisol (Cushing’s syndrome)
• Fasting glucose, OGTT – to assess insulin resistance/diabetes
o Look for impaired glucose tolerance/type 2 DM – fasting glucose
(N - <6.1
impaired fasting glucose – 6.1-6.9
diabetes >7)
HbA1c (>6.5%, >48mm)
if either of these are abnormal, do an OGTT

• Assess CV risk, incl. lipid levels
o Fasting lipid profile – raised total cholesterol, LDL, triglycerides, low HDL – dyslipidaemia often observes in PCOS

19
Q

Subfertility investigations - history

A

• Ask about general health – weight, smoking, drinking, recreational drugs

• Ask about sexual history
o Frequency of coitus (ideally 2-3x/7)
o Any prolonged/recurrent absences of one of the partners
o Potential physical problems – inadequate penetration or dyspareunia

• PMH
o Previous treatment for malignancy – chemo (sterility), radiotherapy and surgery (may be relevant if they involved the pelvic region)
o Systemic disease (may interfere with the HPA axis)
 Autoimmune disease – rheumatoid disease, SLE, APL
 CKD
 Poorly controlled DM
 Anorexia nervosa – can cause anovulation amenorrhoea

• Medication and drug history
o Phenothiazines + older typical antipsychotics + metoclopramide – can increase levels of prolactin
o NSAID use is associate with luteinised unruptured follicles
o Immunosuppressants

20
Q

Subfertility investigations - examination

A

Examination
• Increased androgen levels
o Hirsutism
o Acne
o Male pattern alopecia with slight bitemporal recession
o Pubic hairline may extend up towards the umbilicus in a typical male pattern

• Abdominal examination must precede bimanual pelvic examination
o Very easy to miss a large mass e.g. big ovarian cyst

• Gynaecological examination
o May indicate undisclosed sexual difficulties e.g. vaginismus

• Bimanual examination
o Adnexal mass from an ovary of tubo-ovarian mass
o Tenderness suggesting PID or endometriosis
o Presence of uterine fibroids

21
Q

Subfertility investigations - primary care

A

• Mid-luteal progesterone level – to assess + confirm ovulation
o If low, may need repeating as ovulation does not occur every month
o Blood test is taken 7 days before the anticipated period (i.e. on day 21 of a 28 day cycle)
o If POI you cannot do this – there are no periods to base the measurement off
<16 nmol/l - repeat, if consistently low refer to a specialist
16-30 nmol/l - repeat
>30 nmol/l - indicated ovulation

• FSH + LH – should be measured if there is menstrual irregularity
o High levels – may suggest poor ovarian function
o A comparatively high LH level relative to FSH – can occur in PCOS

• Test for rubella status
o If susceptible to rubella – vaccinate + advise not to become pregnant for at least one month following vaccination

22
Q

Subfertility investigations - secondary care

A

• TUBAL PATENCY – tubal damage is estimated to account for 20% of infertility in women

o	Hysterosalpingogram (HSG) or hysterosalpingo-contrast USS
	For women who are not known to have comorbidities (e.g. PID, ectopic pregnancy, endometriosis)

o Laparoscopy and dye test
 For women who have comorbidities

o Prior to undergoing uterine instrumentation, offer women screening for Chlamydia trachomatis + treat appropriately
o Prophylactic antibiotics should be considered before uterine instrumentation if screening has not been undertaken

• OVARIAN RESERVE TESTING
o Woman’s age should be used as an initial predictor of her overall chance of success through natural conception or with IVF
o One of the following measures should be used (measured around Day 3 of the menstrual cycle) to predict the likely ovarian response to gonadotrophin stimulation in IVF
 Total antral follicle count (TVUS)
• <4 – low response
• >16 – high response
 Anti-Mullerian hormone – will be low in infertility
• <5.4 pmol/L – low response
• >25.0 pmol/L – high response
 FSH – will be high in infertility – inaccurate during the luteal phase as it is being suppressed by progesterone
• >8.9 IU/L – low response
• <4 IU/L – high response

o People undergoing IVF should be offered screening for (if positive – offer specialist advice + counselling + appropriate clinical management)
 HIV
 Hep B
 Hep C

23
Q

Subfertility ix

A

• Semen analysis

• Blood hormone profile
o Look at early follicular phase FSH, LH and oestradiol levels (day 2-3)
o AMH – assesses ovarian reserve
 Independent of the menstrual cycle
 Produced by granulosa cells and does not change in response to gonadotrophins – it is the most successful biomarker of ovarian reserve
o Mid-luteal progesterone – used to confirm ovulation
o If irregular menstrual cycle – TFTs, prolactin, testosterone

• Ovarian reserve testing

• Regularity of menstrual cycles
o Ask about frequency + regularity of menstrual cycles
o Regular monthly menstrual cycles – women are likely ovulating
o Mid-luteal progesterone level
o If prolonged irregular menstrual cycles - blood test for serum progesterone (Conducted later in the cycle e.g. day 28 of a 35-day cycle, Repeated weekly thereafter until the next menstrual cycle starts) + blood test for serum gonadotrophins (FSH, LH)

• Prolactin measurement
o Should only be offered to women who have an ovulatory disorder, galactorrhoea or a pituitary tumour

• Investigation of suspected tubal + uterine abnormalities
o Not known to comorbidities – Hysterosalpingography (HSG) or hysterosalpingo-contrast-ultrasonography – screens for tubal occlusion
o Comorbidities – laparoscopy + dye (so that tubal + pelvic pathology can be assessed at the same time)
o Should not be offered hysteroscopy unless clinically indicated

• Testing for viral status
o People undergoing IVF should be offered testing for HIV, Hep B, Hep C

• Susceptibility to rubella

• Screening for Chlamydia trachomatis
o Before undergoing uterine instrumentation women should be offered screening for Chlamydia trachomatis
o Prophylactic antibiotics should be considered before uterine instrumentation if screening has not been undertaken

•	TVUS 
o	Assessment of pelvic anatomy
o	Identify pathology
o	Antral follicle count (important parameter of ovarian reserve)
	<4 = poor response
	16+ = good response
24
Q

When to refer the woman earlier for infertility ix in secondary care

A

• An earlier referral for specialist consultation should be offered when
o Woman is >36 y/o
o There is a known cause of infertility
o There is hx of predisposing factors for infertility
o Ix show there is apparently no chance of pregnancy with expectant management

25
Q

Semen analysis reference values

	Semen volume 
	pH 
	sperm concentration 
	total sperm number 
	total motility (progressive motility + non-progressive motility) 
	vitality 
	sperm morphology (normal forms)

Further ix if… are…
o If the result of semen analysis is abnormal
o If gross spermatozoa deficiency (azoospermia or severe oligozoospermia) has been detected

A

o Reference values
 Semen volume – >1.5 ml
 pH - >7.2
 sperm concentration – >15 million spermatozoa per ml
 total sperm number - >39 million spermatozoa per ejaculate or more
 total motility (progressive motility + non-progressive motility) - >40% motile, >32% progressively motile
 vitality - >58% live spermatozoa
 sperm morphology (normal forms) >4%

o If the result of semen analysis is abnormal –> repeat confirmatory test 3 months after the initial analysis (allow time for the cycle of spermatozoa formation to be completed)

o If gross spermatozoa deficiency (azoospermia or severe oligozoospermia) –> repeat test should be undertaken asap

26
Q

Endometrial hyperplasia ix

A

• Diagnosis requires histological examination of the endometrial tissue

• TVUS to diagnose endometrial hyperplasia
o <4mm – endometrial cancer unlikely
o >4mm – hysteroscopy +/- biopsy

• Diagnostic hysteroscopy + biopsy

27
Q

Endometrial cancer ix

A

• TVUS
o First-line for women with PMB
o The mean endometrial thickness in postmenopausal women is much thinner than in premenopausal women
o <4mm – endometrial cancer unlikely
o >4mm – hysteroscopy +/- biopsy
o Malignant and benign endometrial patterns can often be determined by TVUS which can help diagnosis

• Hysteroscopy +/- Biopsy
o In OP under LA
o Preferred diagnostic technique to detect polyps + other benign lesions
o High diagnostic accuracy for – endometrial cancer, polyps, submucous myomas
o Moderate diagnostic accuracy for – endometrial hyperplasia

• Other
o Many women will also have CXR and blood tests (FBC, LFTS)

•	Staging
o	TAH + BSO - primary treatment + staging 
o	FIGO staging
	I – limited to uterus 
	II – spread to cervix
	III – spread adjacent
	IV – distant spread 

• Lynch syndrome testing for women with endometrial cancer
o All women diagnosed with endometrial cancer should be offered testing for lynch syndrome
o The inherited condition Lynch syndrome increases the risk of certain types of cancer incl. endometrial and colorectal cancer

28
Q

FIGO endometrial cancer staging

A

 I – limited to uterus
 II – spread to cervix
 III – spread adjacent
 IV – distant spread

https://geekymedics.com/wp-content/uploads/2014/01/endometrial-cancer-staging.jpg

29
Q

Ovarian cancer ix in primary care

A
•	Ca125 
o	>35 IU/ml --> 2WW referral + TVUS of the abdomen + pelvis 
o	Normal (<35 IU/ml) or high Ca125 but normal US --> assess carefully other clinical causes of her symptoms + ix if appropriate, safety net – return to GP if symptoms become more frequent and/or persistent 

o CA125 raised in
 >80% epithelial ovarian cancers
 Also raised in pregnancy, endometriosis, alcoholic liver disease
o Should be the only tumour marker used for primary evaluation – allows the risk of malignancy index of ovarian cysts in postmenopausal women to be calculated

30
Q

Ovarian cancer ix in secondary care

A

• Ca 125 – 1st line

• TVUS – 1st line – ordered by gynaecology, not GP – characterise
o Size
o Consistency
o Bilateral or not
o Presence of solid elements
o Presence of ascites
o Extraovarian disease – peritoneal thickening, omental deposits

• Risk malignancy Index 1 – 1st line
o To assess likelihood of malignancy
 If >250 (NICE) or >200 (SIGN, RCOG) – high risk, CT abdomen pelvis, refer to a specialised multidisciplinary team
 <25 – low risk

• Imaging – staging
o TVUS abdomen pelvis – first imaging test in secondary care for suspected ovarian cancer
o If US, CA125 + clinical status suggest ovarian cancer –> CT abdomen pelvis
o Do not use MRI

• Biopsy
o Percutaneous image-guided biopsy
o Laparoscopic biopsy – if percutaneous image-guided biopsy is not feasible/has not produced an adequate sample
o (if offering cytotoxic chemotherapy to women with suspected advanced ovarian cancer, first obtain a confirmed tissue diagnosis by histology (or by cytology if histology is not appropriate) in all but exceptional cases)

• If <40 y/o
o Exclude endodermal sinus tumours – AFP
o Identify women who may have dysgerminomas, embryonal carcinomas or choriocarcinomas –βhcg
o LDH, AFP, hCG – should all be measured in all women <40 with a complex ovarian mass - ?germ cell tumours

31
Q

Ovarian cancer staging

A

FIGO

Stage I - limited to ovaries
Stage II - Limited to pelvis
Stage III - Limited to abdomen
Stage IV - outside abdominal cavity

https: //miro.medium.com/max/842/1*JjBWhX3bd8p6YLhdjsTkQw.png
https: //www.researchgate.net/profile/Athina-Tsili/publication/266126977/figure/tbl1/AS:668226933510156@1536329124256/FIGO-staging-of-ovarian-cancer.png (+ look at notes)

32
Q

When to investigate for ovarian cancer in primary care?

When to refer?

A

• Tests in primary care to be carried out if the woman (esp. >50) reports having ay of the following symptoms on a persistent or frequent basis, particularly >12 times per month
o Persistent abdominal distension – “bloating”
o Early satiety +/or loss of appetite
o Pelvic or abdominal pain
o Increased UU and/or frequency
o Unexplained weight loss, fatigue, changes in bowel habit

• Appropriate tests for ovarian cancer in any woman >50 who has experienced symptoms within the previous 12 months that suggest IBS –> IBS rarely presents for the first time in women of this age

REFERAL
• Ca125
o >35 IU/ml –> 2WW referral + TVUS of the abdomen + pelvis
• Urgent referral (2WW) to a gynaecological cancer service if physical examination identified: a) ascites and/or pelvic/abdominal mass

33
Q

Risk of malignancy index calculation

A

o Score = US score x menopausal score x CA125 level in IU/ml

 US score = the number of the following findings on scan
• Multilocular cyst
• Solid areas
• Bilateral lesions
• Ascites
• Intra-abdominal metastases
• U=O (US score = 0), U=1 (US score 1), U=3 (US score 2-5)

 Menopausal status
• 1=pre-menopausal
• 3=postmenopausal

34
Q

• Assessing response to chemotherapy + monitoring efficacy of treatment + monitoring for recurrence in ovarian cancer

A

o CA 125

o (Imaging) – CT scan

35
Q

Ovarian cysts ix in premenopausal women

A
  • Pregnancy test
  • Germ cell tumours - raised AFP, raised βHCG

• Physical examination
o Abdominal + vaginal examination
o Presence/absence of local lymphadenopathy
o Evaluation of mass tenderness, mobility, nodularity, ascites

• Acute presentation - ?accident to the ovarian cyst (torsion, rupture, haemorrhage)

• TVUS>TAUS
o Single most effective way of evaluating an ovarian mass
o Can be used to estimate accurately the risk of malignancy in premenopausal women without a ca125
o Simple - manage depending on size
50-70mm yearly TVUS <50mm no f/u, likely to be physiological

o Complex (<40y/o) - LDH, AFP, bHCG levels – should all be measured in all women <40 with a complex ovarian mass - ?germ cell tumours

• Bloods
o Ca125 - Does not need to be done in premenopausal women who have had an US dx of a simple ovarian cyst made
 Can be raised in numerous conditions e.g. fibroids, endometriosis, adenomyosis, pelvic infection
 If it’s raised – serial monitoring – rapidly rising levels are more likely to be associated with malignancy
 <200 units/ml – exclude/treat the common differential diagnoses
 >200 units/ml – discussion with the gynaecological oncologist
o <40 – LDH, AFP, hCG – should all be measured in all women <40 with a complex ovarian mass - ?germ cell tumours
 Exclude endodermal sinus tumours – AFP
 Identify women who may have dysgerminomas, embryonal carcinomas or choriocarcinomas –βhcg

• Risk of malignancy index (RMI)
o To estimate the risk of malignancy
o Essential in the assessment of an ovarian mass
o However results may not be applicable to the premenopausal group –

• Refer if (American college of obstetric and gynaecologists + society of obstetricians and gynaecologists)
o Ca125 >200 units/ml
o Evidence of abdominal/distant mets
o First degree relative with breast/ovarian cancer

https://static.cambridge.org/binary/version/id/urn:cambridge.org:id:binary:20170425111408716-0064:9781316537398:50992fig22_2.png?pub-status=live

36
Q

Tumour markers

ca125
ca19-9
cea
inhibin
AFP
HER2
LDH
bHCG
A

ca125 - serous epithelial ovarian cancer
ca19-9 - mucinous epithelial ovarian cancer
pancreatic cancer

cea - bowel cancer

inhibin - granulosa cell tumours

AFP
liver cancer
endodermal yolk sac tumour
teratoma

HER2
breast cancer (receptor)

LDH
Dysgerminoma

bHCG
Dysgermioma
choriocarcinoma

37
Q

Ovarian cysts ix in postmenopausal women

A

• Full physical examination
o BMI
o Abdominal examination to detect ascites + characterise any palpable mass - Evaluation of mass tenderness, mobility, nodularity, ascites
o Vaginal examination
o Presence/absence of local lymphadenopathy

• Ca125
o Should not be used in isolation to determine if the cyst is malignant – a normal value does not exclude ovarian cancer
o Monitoring ca125 levels may be helpful – rapidly rising levels more likely to be associated with malignancy than high levels which remain static
o Main use of ca125 – assessing response over time to treatment for malignancy
o >35 IU/ml -2WW referral + TVUS of the abdomen + pelvis
o Normal (<35 IU/ml) or high Ca125 but normal US - assess carefully other clinical causes of her symptoms + ix if appropriate, safety net – return to GP if symptoms become more frequent and/or persistent

• TVUS
o First line imaging ix
o Single most effective way of evaluating ovarian cysts in postmenopausal women
o Transabdominal US should not be used in isolation – only to provide supplementary information to the TVUS (e.g. when an ovarian cyst is large or beyond the field of view of TVUS)
o Simple or complex - use CA-125 level - RMI calculation

• MRI
o Second line
o Used if TVUS is inconclusive

• CT abdomen and pelvis
o If malignant disease is suspected based on the US findings and tumour markers

• Risk malignancy Index 1
o To assess likelihood of malignancy
 If >250 (NICE) or >200 (SIGN, RCOG) – high risk, CT abdomen pelvis, refer to a specialised multidisciplinary team –
 <25 – low risk

  • FBC – infection, haemorrhage
  • Urinalysis – if there are urinary symptoms
  • CT/MRI – only required if US results are not definitive or if intra-abdominal pathology is suspected
  • Diagnostic laparoscopy
  • FNA + cytology to confirm that the cyst is benign

https://static.cambridge.org/binary/version/id/urn:cambridge.org:id:binary:20170425111408716-0064:9781316537398:50992fig22_2.png?pub-status=live

38
Q

Elevated ca125 ddx

A
Ovarian cancer
Endometriosis
uterine fibroids
menstruation
pregnancy
benign ovarian neoplasms
>80% epithelial ovarian cancers

Alcoholic liver disease
Diverticulitis
Liver cirrhosis
other malignancies (pancreatic, breast, liver, lung)

39
Q

Sonographic evidence (US) dx

Beads on a string

Snowstorm appearance

Whirpool sign

Hypoechoic mass

A

Chronic salpingitis/Hydrosalpinx
mural nodules appearing as ‘beads’ and the relatively-thin wall appearing as ‘string’.

Complete hydatidiform mole/molar pregnancy

Ovarian torsion
https://www.youtube.com/watch?v=5x3FhvWgqJs

Fibroid

40
Q

Liachen sclerosus ix

A
  • Diagnosis is usually made clinically by clinical appearance
  • Lesions should be well documented for follow up purposes – diagrams + photography

• Other investigations
o Biopsy
 Indicated only when there is diagnostic uncertainty or suspected malignancy (coexistent vulval intraepithelial neoplasia (VIN)/SCC suspicion)
 Should be considered when presentation is atypical e.g. young adult women, extragenital lesions, pigmented lesions, development of raised lesions
 Essential if lesions do not respond to initial course of steroid treatment
 Findings – thinned epidermis with sub-epidermal hyalinization and deeper inflammatory infiltrate

o Blood tests
 If there are clinical features to suggest an AI disorder– autoantibody screen
 if symptoms present – autoimmune screen, TFTs

41
Q

Ix/ considerations before TOP

A

Considerations before TOP
• Counselling/support
o Verbal advice + written information
o Additional support/counselling if needed (evidence of coercion, poor social support, psychiatric history)
• Blood tests
o Hb
o Blood group + antibodies
o If clinically indicated – HIV, HBV, HCV, haemoglobinopathies
• USS – to give accurate gestation + identify already non-viable and occasional ectopic pregnancies
• Prevention of infection – screen for lower genital tract infections e.g. Chlamydia (with treatment + contact tracing if +ve)